Metabolic Dysfunction-Associated Steatohepatitis

Test your knowledge of the four interrelated conditions driving cardiometabolic risk and how early intervention can alter disease progression.

With the approval of resmetirom and GLP-1 receptor agonists showing promise as a potential treatment option, the management of metabolic dysfunction-associated steatohepatitis (MASH) is rapidly evolving....

Metabolic dysfunction–associated steatohepatitis is becoming increasingly common in patients with type 2 diabetes and other metabolic risk factors. Test your knowledge of the key diagnostic features,...

Test your knowledge on the prevalence of nonalcoholic steatohepatitis in the United States by taking our short pop quiz!

Individuals with MASH and significant liver fibrosis have a higher risk for serious liver-related outcomes compared with those with simple steatosis. Which endpoint should be a target for treatment: MASH...

In 2025, Consultant360’s most engaging quizzes challenged practitioners across specialties to test and refine their knowledge on pivotal topics—from rehabilitation in chronic disease to advances in mental...